[CAS NO. 906093-29-6] Teneligliptin hydrobromide

Name: Teneligliptin hydrobromide
Brand: Arctom Scientific
SKU: SLK-S4636

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [906093-29-6]

Store

Catalog

SLK-S4636

Brand

Selleck

CAS

906093-29-6

DESCRIPTION [906093-29-6]

Overview

MDL	MFCD23098790
Molecular Weight	628.86
Molecular Formula	C22H30N6OS.5/2HBr
SMILES	O=C(N1CSCC1)[C@H]2NC[C@H](C2)N3CCN(CC3)C4=CC(C)=NN4C5=CC=CC=C5.[H]Br.[H]Br.[H]Br.[H]Br.[H]Br.O=C(N6CSCC6)[C@H]7NC[C@H](C7)N8CCN(CC8)C9=CC(C)=NN9C%10=CC=CC=C%10

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	1.5902 mL	7.9509 mL	15.9018 mL
5 mM	0.3180 mL	1.5902 mL	3.1804 mL
10 mM	0.1590 mL	0.7951 mL	1.5902 mL
50 mM	0.0318 mL	0.1590 mL	0.3180 mL

Description

Teneligliptin (Teneligliptin hydrobromide anhydrous) is a novel, potent, and long-lasting inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant in vitro, with values of approximately 1 nM.

Targets

DPP-4 ^[1]	DPP-9 ^[1]
1.75 nM	150 nM

In vitro

Chronic teneligliptin treatment at doses between 0.1 and 3.0 µmol/L does not reduce cell viability of HUVECs, but decreases HG-stress markers and increases heme oxygenase-1 (HMOX1) gene expression in HUVEC cells incubated under hyperglycemia. Also, chronic teneligliptin treatment improves proliferative capacities of HUVEC cells and endoplasmic reticulum (ER) function in HUVEC cells exposed to HG. Teneligliptin has antioxidant properties under NG in HUVECs, reducing ROS levels and initiating the transcriptional cascade of the antioxidant genes.

References

[1] Kishimoto M, et al. Diabetes Metab Syndr Obes. 2013, 6:187-95.
[2] Sameshima A, et al. J Endocrinol. 2015, 227(1):25-36.
[3] Ideta T, et al. Int J Mol Sci. 16(12):29207-18.
[4] Pujadas G, et al. Endocrine. 2016, [Epub ahead of print].
[5] Fukuda-Tsuru S, et al. Eur J Pharmacol. 2012 Dec 5;696(1-3):194-202.